Advertisement

The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010

Published:December 02, 2013DOI:https://doi.org/10.1016/j.jhep.2013.11.014

      Background & Aims

      In light of the dramatically changing hepatitis C therapeutic landscape, knowledge of the current burden of HCV infection in the general population of the United States is critical.

      Methods

      The National Health and Nutrition Examination survey collects nationally representative data on HCV infection in the civilian population of the United States. Data from 2001 to 2010 were combined for this study. HCV testing was completed in 38,025 participants.

      Results

      The prevalence of anti-HCV in the United Sates decreased from 1.9% (95% CI 1.5%–2.5%) in 2001–2002 to 1.3% (95% CI 0.9%–1.8%) in 2005–2006, and remained stable up to 2010. About 67% of all infected persons were positive for HCV RNA, indicating 2.3 million people with chronic HCV infection, of whom 68% have genotype 1. Seventy percent of infected persons were born between 1945 and 1965, with prevalence of 3.5% (95% CI 2.2%–4.8%). The stable rate since 2006 is mostly related to prevalent cases and foreign born persons migrating into US. Other important risk factors include less education and low economic status. Race, HIV status, number of sexual partners, and blood transfusions are no longer associated with HCV infection.

      Conclusions

      As of 2010, approximately 2.3 million persons were chronically infected with Hepatitis C in the US. Most of those infected are prevalent, rather than incident cases. The prevalence of HCV was on the decline, but has stabilized since 2006. Future studies should explore reasons for no decline in HCV prevalence since 2006.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alter M.J.
        • Kruszon-Moran D.
        • Nainan O.V.
        • McQuillan G.M.
        • Gao F.
        • Moyer L.A.
        • et al.
        The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.
        N Engl J Med. 1999; 341: 556-562
        • Lauer G.M.
        • Walker B.D.
        Hepatitis C virus infection.
        N Engl J Med. 2001; 345: 41-52
        • Alter M.J.
        Epidemiology of hepatitis C virus infection.
        World J Gastroenterol. 2007; 13: 2436-2441
        • Seeff L.B.
        Natural history of chronic hepatitis C.
        Hepatology. 2002; 36: S35-S46
        • Tan J.
        • Lok A.S.
        Update on viral hepatitis: 2006.
        Curr Opin Gastroenterol. 2007; 23: 263-267
        • Armstrong G.L.
        • Wasley A.
        • Simard E.P.
        • McQuillan G.M.
        • Kuhnert W.L.
        • Alter M.J.
        The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.
        Ann Intern Med. 2006; 144: 705-714
      1. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance, United States 2010. 2012:1–71. Accessed at www.cdc.gov/hepatitis/Statistics/2010Surveillance/Commentary.htm on 10 July; 2012. Ref Type: Generic.

        • Davis G.L.
        • Albright J.E.
        • Cook S.F.
        • Rosenberg D.M.
        Projecting future complications of chronic hepatitis C in the United States.
        Liver Transpl. 2003; 9: 331-338
        • Rein D.B.
        • Wittenborn J.S.
        • Weinbaum C.M.
        • Sabin M.
        • Smith B.D.
        • Lesesne S.B.
        Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States.
        Dig Liver Dis. 2011; 43: 66-72
      2. Recommendations for prevention and control of hepatitis, C virus (HCV) infection and HCV-related chronic disease. Centers for disease control and prevention.
        MMWR Recomm Rep. 1998; 47: 1-39
        • Moyer VA.
        Screening for hepatitis C virus infection in adults: U.S. Preventive services task force recommendation statement.
        Ann Intern Med. 2013; 159: 349-357https://doi.org/10.7326/0003-4819-159-5-201309030-00672
      3. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. public health service (USPHS) and infectious diseases society of America (IDSA).
        MMWR Recomm Rep. 1999; 48: 1-6
        • Cheung R.
        • Mannalithara A.
        • Singh G.
        Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US.
        Dig Dis Sci. 2010; 55: 1744-1751
        • Volk M.L.
        • Tocco R.
        • Saini S.
        • Lok A.S.
        Public health impact of antiviral therapy for hepatitis C in the United States.
        Hepatology. 2009; 50: 1750-1755
        • Denniston M.M.
        • Klevens R.M.
        • McQuillan G.M.
        • Jiles R.B.
        Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National health and nutrition examination survey 2001–2008.
        Hepatology. 2012; 55: 1652-1661
        • Dhingra K.
        • Talpaz M.
        • Dhingra H.M.
        • Ajani J.A.
        • Rothberg J.M.
        • Gutterman J.U.
        A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum.
        Invest New Drugs. 1991; 9: 37-39
        • Southern W.N.
        • Drainoni M.L.
        • Smith B.D.
        • Christiansen C.L.
        • McKee D.
        • Gifford A.L.
        • et al.
        Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting.
        J Viral Hepat. 2011; 18: 474-481
        • Spradling P.R.
        • Rupp L.
        • Moorman A.C.
        • Lu M.
        • Teshale E.H.
        • Gordon S.C.
        • et al.
        Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence.
        Clin Infect Dis. 2012; 55: 1047-1055
      4. Centers for Disease Control and Prevention. About the National Health and Nutrition Examination Survey (NHANES) Available at www.cdc.gov/nchs/about/major/nhanes/intro_mec.htm. Accessed on May 13, 2013. N/A; 2009.

        • Alter M.J.
        • Margolis H.S.
        • Krawczynski K.
        • Judson F.N.
        • Mares A.
        • Alexander W.J.
        • et al.
        The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team.
        N Engl J Med. 1992; 327: 1899-1905
        • Mohd H.K.
        • Groeger J.
        • Flaxman A.D.
        • Wiersma S.T.
        Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.
        Hepatology. 2013; 57: 1333-1342
        • Williams I.T.
        • Bell B.P.
        • Kuhnert W.
        • Alter M.J.
        Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006.
        Arch Intern Med. 2011; 171: 242-248
        • Smith B.D.
        • Morgan R.L.
        • Beckett G.A.
        • Falck-Ytter Y.
        • Holtzman D.
        • Ward J.W.
        Hepatitis C virus testing of persons born during 1945–1965: recommendations from the centers for disease control and prevention.
        Ann Intern Med. 2012; 157: 817-822
        • Magiorkinis G.
        • Sypsa V.
        • Magiorkinis E.
        • Paraskevis D.
        • Katsoulidou A.
        • Belshaw R.
        • et al.
        Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics.
        PLoS Comput Biol. 2013; 9: e1002876
        • Armstrong G.L.
        • Alter M.J.
        • McQuillan G.M.
        • Margolis H.S.
        The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.
        Hepatology. 2000; 31: 777-782
        • Jacobson I.M.
        • McHutchison J.G.
        • Dusheiko G.
        • Di Bisceglie A.M.
        • Reddy K.R.
        • Bzowej N.H.
        • et al.
        Telaprevir for previously untreated chronic hepatitis C virus infection.
        N Engl J Med. 2011; 364: 2405-2416
        • Kowdley K.V.
        • Lawitz E.
        • Crespo I.
        • Hassanein T.
        • Davis M.N.
        • DeMicco M.
        • et al.
        Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
        Lancet. 2013; 381: 2100-2107
        • Poordad F.
        • McCone Jr., J.
        • Bacon B.R.
        • Bruno S.
        • Manns M.P.
        • Sulkowski M.S.
        • et al.
        Boceprevir for untreated chronic HCV genotype 1 infection.
        N Engl J Med. 2011; 364: 1195-1206
        • Schuckman H.
        • Hazelett S.
        • Powell C.
        • Steer S.
        A validation of self-reported substance use with biochemical testing among patients presenting to the emergency department seeking treatment for backache, headache, and toothache.
        Subst Use Misuse. 2008; 43: 589-595
        • Navarro V.J.
        • St Louis T.E.
        • Bell B.P.
        Identification of patients with hepatitis C virus infection in New Haven County primary care practices.
        J Clin Gastroenterol. 2003; 36: 431-435
        • Alter M.J.
        • Gerety R.J.
        • Smallwood L.A.
        • Sampliner R.E.
        • Tabor E.
        • Deinhardt F.
        • et al.
        Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population.
        J Infect Dis. 1982; 145: 886-893
        • Alter M.J.
        • Hadler S.C.
        • Judson F.N.
        • Mares A.
        • Alexander W.J.
        • Hu P.Y.
        • et al.
        Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection.
        JAMA. 1990; 264: 2231-2235
        • Alter M.J.
        Epidemiology of hepatitis C.
        Hepatology. 1997; 26: 62S-65S
        • Mehta S.H.
        • Astemborski J.
        • Kirk G.D.
        • Strathdee S.A.
        • Nelson K.E.
        • Vlahov D.
        • et al.
        Changes in blood-borne infection risk among injection drug users.
        J Infect Dis. 2011; 203: 587-594
        • Hagan H.
        • Campbell J.
        • Thiede H.
        • Strathdee S.
        • Ouellet L.
        • Kapadia F.
        • et al.
        Self-reported hepatitis C virus antibody status and risk behavior in young injectors.
        Public Health Rep. 2006; 121: 710-719
        • Hagan H.
        • Des J.
        • Stern R.
        • Lelutiu-Weinberger C.
        • Scheinmann R.
        • Strauss S.
        • et al.
        HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection.
        Int J Drug Policy. 2007; 18: 341-351
        • Martin N.K.
        • Vickerman P.
        • Miners A.
        • Foster G.R.
        • Hutchinson S.J.
        • Goldberg D.J.
        • et al.
        Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.
        Hepatology. 2012; 55: 49-57
        • Page K.
        • Morris M.D.
        • Hahn J.A.
        • Maher L.
        • Prins M.
        Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention.
        Clin Infect Dis. 2013; 57: S32-S38
        • Page K.
        • Hahn J.A.
        • Evans J.
        • Shiboski S.
        • Lum P.
        • Delwart E.
        • et al.
        Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.
        J Infect Dis. 2009; 200: 1216-1226
        • Shehab T.M.
        • Orrego M.
        • Chunduri R.
        • Lok A.S.
        Identification and management of hepatitis C patients in primary care clinics.
        Am J Gastroenterol. 2003; 98: 639-644
        • Di S.R.
        • Stroffolini T.
        • Ferraro D.
        • Usticano A.
        • Valenza L.M.
        • Montalbano L.
        • et al.
        Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission.
        J Med Virol. 2002; 67: 339-344
        • Guadagnino V.
        • Stroffolini T.
        • Caroleo B.
        • Menniti I.F.
        • Rapicetta M.
        • Ciccaglione A.R.
        • et al.
        Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection.
        Dig Liver Dis. 2013; 45: 403-407
        • Maio G.
        • d’Argenio P.
        • Stroffolini T.
        • Bozza A.
        • Sacco L.
        • Tosti M.E.
        • et al.
        Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town.
        J Hepatol. 2000; 33: 116-120
        • Tohme R.A.
        • Holmberg S.D.
        Is sexual contact a major mode of hepatitis C virus transmission?.
        Hepatology. 2010; 52: 1497-1505
        • Alter H.J.
        • Houghton M.
        Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis.
        Nat Med. 2000; 6: 1082-1086
        • Donahue J.G.
        • Munoz A.
        • Ness P.M.
        • Brown Jr., D.E.
        • Yawn D.H.
        • McAllister Jr., H.A.
        • et al.
        The declining risk of post-transfusion hepatitis C virus infection.
        N Engl J Med. 1992; 327: 369-373